Prostate Cell News Volume 10.09 | Mar 15 2019

TOP STORY

Replication Study: The MicroRNA miR-34a Inhibits Prostate Cancer Stem Cells and Metastasis by Directly Repressing CD44

Scientists found the microRNA, miR-34a, was expressed at twice the level in CD44⁺ prostate cancer cells purified from xenograft tumors compared to CD44^– LAPC4 cells, whereas the original study reported miR-34a was underexpressed in CD44⁺ LAPC4 cells [eLife] Full Article

(Ranked by impact factor of the journal)

Oncogenic and Osteolytic Functions of Histone Demethylase NO66 in Castration-Resistant Prostate Cancer

Forced expression of NO66 promoted cell survival and invasion of prostate cancer cells; whereas, knockdown of NO66 resulted in decreased cell survival and increased sensitivity to docetaxel. [Oncogene] Abstract

Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNF Alpha in Castration Resistant Prostate Cancer

Single-cell mRNA sequencing was conducted to compare the transcriptomes of SULT2B1b knockdown (KD) versus control KD LNCaP cells. Over 2,000 differentially expressed genes were identified along with alterations in numerous canonical pathways, including the death receptor signaling pathway. [Mol Cancer Res] Abstract

Differential Effect of Grape Seed Extract and Its Active Constituent Procyanidin B2 3,3″‐di‐O‐Gallate against Prostate Cancer Stem Cells

Cancer stem cell populations were isolated and purified based on CD44⁺‐α2β1^high surface markers in prostate cancer cell lines LNCaP, C4‐2B, 22Rv1, PC3, and DU145, and then subjected to prostasphere formation assays in the absence or presence of grape seed extract or B2 3,3″‐di‐O‐gallate. [Mol Carcinog] Abstract

Clinical Utility of Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA as a Biomarker for Treatment of Castration-Resistant Prostate Cancer

Scientists established a highly sensitive method for analyzing androgen receptor gene (AR) copy numbers and mutations in plasma circulating cell-free DNA and evaluated the AR statuses of patients with castration-resistant prostate cancer. [Sci Rep] Full Article

A Novel Approach for Assessment of Prostate Cancer Aggressiveness Using Survivin-Driven Tumor-Activatable Minicircles

Researchers assessed the ability of tumor-activatable minicircles to detect and characterize primary prostate lesions. The minicircles produced reporter levels related to survivin expression across a range of prostate cancer cell lines. [Gene Ther] Abstract

Combination of Phospholipase Cε Knockdown with GANT61 Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide by Suppressing the Androgen Receptor Signaling Pathway

The expression of phospholipase Cε (PLCε) and glioma-associated homolog-1/Gli-2 in benign prostatic hyperplasia, prostate cancer and castration-resistant prostate cancer (CRPC) tissues and cells was investigated, and the correlations between PLCε and Gli-1/Gli-2 in CRPC tissues and cell lines were further explored. [Oncol Rep] Abstract

Effect of Docetaxel on the Regulation of Proliferation and Apoptosis of Human Prostate Cancer Cells

The authors investigated the effect of docetaxel on androgen receptor (AR)-dependent and AR-independent prostate cancers cells. [Mol Med Rep] Abstract

KHC-4 Inhibits β-Catenin Expression in Prostate Cancer Cells

Investigators found that KHC-4 could inhibit β-catenin expression and its signaling pathway in DU145 prostate cancer cells. Treatment with KHC-4 decreased total β-catenin expression and concomitantly decreased β-catenin levels in both the cytoplasm and nucleus of cells. [Biotech Histochem] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Androgen Receptor Enhancer Usage and the Chromatin Regulatory Landscape in Human Prostate Cancers

The authors provide an overview of the different factors that influence androgen receptor chromatin binding in prostate cancer specimens, which is complemented with knowledge from cell line studies. [Endocr Relat Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

First Patient Dosed in a Phase II Study with LiPlaCis in Prostate Cancer

Oncology Venture A/S announced that the first patient has been dosed in a Phase II study with LiPlaCis^® in prostate cancer. Oncology Venture has clearance from the Danish health authorities to treat up to 15 prostate cancer patients with LiPlaCis^®. [Oncology Venture A/S] Press Release

Flow Pharma, Inc. and OncoImmunity AS Partner for the Development of FlowVax™ Personalized Cancer Vaccines

Flow Pharma Inc. announced a collaboration with OncoImmunity AS. Under the agreement OncoImmunity will license the Immuneoprofiler™ software to Flow Pharma to support the clinical development and commercialization of products based on the FlowVax platform. [Flow Pharma Inc. (Business Wire, Inc.)] Press Release

Survey Highlights “Shocking” Gender Bias Among PI Pay in UK

Organizers of a survey of early-career scientists in the UK say they are shocked by the picture it paints of gender bias in British science. Women principal investigators (PIs) who have started their own lab in recent years are paid thousands of pounds a year less than men at the same stage of their career, the results show. [The Scientist] Editorial

Norway Joins List of Countries Canceling Elsevier Contracts

Norway has become latest country to cancel its contracts with Elsevier following a dispute over access to research papers. In a statement published March 12, the Norwegian Directorate for ICT and Joint Services in Higher Education and Research, which represents a consortium of research institutions in the country, rejected Elsevier’s offer to lower some of its costs for Norwegian institutions because it didn’t go far enough to promote free access to published research. [The Scientist] Editorial

NEW Gordon Research Seminar: Overcoming Endocrine Resistance and Metastasis in Hormone-Dependent Cancers
August 3-4, 2019
Newry, Maine, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Prostate Cancer (UT Health San Antonio)

Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Faculty Position – Prostate Cancer Biology and Cancer Epigenetics (Northwestern University Feinberg School of Medicine)

Advanced Research Assistant – Cellular Generation and Phenotyping (Wellcome Sanger Institute)

Research Assistant II – Cancer Biology (MD Anderson Cancer Center)

Senior Computational Biologist – Molecular Oncology (Cancer Research UK Manchester Institute)

Postdoctoral Positions – Stem Cell and Cancer Biology (Columbia University Irving Medical Center)

Postdoctoral Fellow – Cancer Biology (Thomas Jefferson University)

Assistant Professor – Translational Cancer Research (Texas Tech University Health Sciences Center El Paso)

Postdoctoral Position – Prostate Cancer (University of Trento)

Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.